Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | EXS21546 |
Synonyms | |
Therapy Description |
EXS21546 is a selective antagonist of the A2A receptor, which potentially decreases tumor cell viability and induces T-cell expansion (Cancer Res (2023) 83 (8_Supplement): CT114). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
EXS21546 | EXS-21546|EXS 21546 | Adenosine Targeting 23 | EXS21546 is a selective antagonist of the A2A receptor, which potentially decreases tumor cell viability and induces T-cell expansion (Cancer Res (2023) 83 (8_Supplement): CT114). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05920408 | Phase Ib/II | EXS21546 | Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours | Terminated | FRA | BEL | 0 |